The protective role of anandamide in mesenteric ischemia reperfusion injury in guinea pig.
BACKGROUND
Acute mesenteric ischemia is an entity characterized by rapid developing of circulatory failure. Reperfusion following ischemia causes further mucosal injury.


METHODS
In our study, an experimental model of 15 minutes of reperfusion following 45 minutes of superior mesenteric artery occlusion was established. The segments which underwent I/R injury were histopathologically examined, and blood samples obtained from the heart were analyzed for alkaline phosphatase and creatine kinase levels.


RESULTS
The results of the study demonstrated that mucosal injury in anandamide injected group was less expressed than in other groups suggesting that anandamide might have a protective effect on the mucosa. After L-NAME and indomethacin injection, the protective effect of anandamide seems to disappear due to inhibition of NO and prostaglandins. The results of histopathological examination of specimens from CB1 receptor and anandamide injected group indicate that I/R injury has regressed.


CONCLUSIONS
The protective effect of endogenous anandamide on I/R injury may take place through CB2 receptors in the small intestine; NO and prostaglandin, which are activated through the stimulation of CB2 receptors may be responsible for this protective effect (Fig. 8, Ref. 29). Full Text (Free, PDF) www.bmj.sk.
Yusifzade
Kenan
K
Department of Surgery, Gazi University Faculty of Medicine, Ankara, Turkey.
Akin
Murat
M
Isikgonul
Ipek
I
Gulbahar
Ozlem
O
Anadol
Ahmet Ziya
AZ
Kurukahvecioglu
Osman
O
Ercan
Sevim
S
Sare
Mustafa
M
D000208:Acute Disease; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology*; D063385:Cannabinoid Receptor Modulators / Q000494:pharmacology; D063388:Endocannabinoids; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006168:Guinea Pigs; D007213:Indomethacin / Q000494:pharmacology; D007413:Intestinal Mucosa / Q000473:pathology; D007583:Jejunum / Q000473:pathology; D008643:Mesentery / Q000098:blood supply*; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000037:antagonists & inhibitors; D053284:Polyunsaturated Alkamides / Q000494:pharmacology*; D015427:Reperfusion Injury / Q000473:pathology / Q000517:prevention & control*
D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D004791:Enzyme Inhibitors; D053284:Polyunsaturated Alkamides; D009569:Nitric Oxide; C078814:anandamide; D019331:NG-Nitroarginine Methyl Ester; D007213:Indomethacin